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Background: Dengue virus (DENV) infection is the most important arthropod- borne viral disease in human, but
antiviral therapy and approved vaccines remain unavailable due to antibody-dependent enhancement (ADE)
phenomenon. Many studies showed that pre-membrane (prM)-specific antibodies do not efficiently neutralize
DENV infection but potently promote ADE infection. However, most of the binding epitopes of these antibodies
remain unknown.
Results: In the present study, we characterized a DENV cross-reactive monoclonal antibody (mAb), 4D10, that
neutralized poorly but potently enhanced infection of four standard DENV serotypes and immature DENV (imDENV)
over a broad range of concentration. In addition, the epitope of 4D10 was successfully mapped to amino acid
residues 14 to18 of DENV1-4 prM protein using a phage-displayed peptide library and comprehensive
bioinformatics analysis. We found that the epitope was DENV serocomplex cross-reactive and showed to be highly
immunogenic in Balb/c mice. Furthermore, antibody against epitope peptide PL10, like 4D10, showed broad
cross-reactivity and weak neutralizing activtity with four standard DENV serotypes and imDENV but significantly
promoted ADE infection. These results suggested 4D10 and anti-PL10 sera were infection-enhancing antibodies and
PL10 was infection-enhancing epitope.
Conclusions: We mapped the epitope of 4D10 to amino acid residues 14 to18 of DENV1-4 prM and found that this
epitope was infection-enhancing. These findings may provide significant implications for future vaccine design and
facilitate understanding the pathogenesis of DENV infection.
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DENV is member of the genus Flavivirus. A sequence
variation of 30% to 35% allows DENV to be divided
into four related but antigenically distinct serotypes
(DENV1-4). DENV represents a major arthropod-borne
pathogen, leading to 390 million infections every year,
mostly in the tropical and subtropical countries. DENV
infection may cause a spectrum of clinical diseases,
such as self-limited dengue fever (DF), potentially life-
threatening dengue hemorrhagic fever (DHF) and dengue* Correspondence: jianglf@mail.sysu.edu.cn
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reproduction in any medium, provided the orshock syndrome (DSS) [1]. In particular, the frequency of
severe DENV infection in travelers visiting dengue en-
demic regions is similar to that of secondary infection in
dengue endemic zones [2]. Although many studies have
attempted to develop promising strategies, a specific anti-
viral agent to DENV infection or an approved vaccine re-
mains unavailable [3,4].
The main obstacle to develop vaccines or specific an-
tiviral therapies to DENV infection is that the im-
munopathogenesis of DENV infection is still not well
known. Infection with one serotype can increase disease
severity upon secondary infection with other serotypes.
Additionally, infants born to dengue-immune mothers
carries an increased risk of severe disease upon primary. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fections is the hypothesis of ADE [7]. According to this
hypothesis, cross-reactive antibodies at sub-neutralizing
concentrations generated during a primary infection has
been suggested to enhance the subsequent infections
by facilitating efficient binding and cell entry of virus-
antibody complexes into Fc receptor-bearing cells [8].
Therefore, an effective dengue vaccine must provide a
protective long-lasting immune response to all four sero-
types; otherwise, vaccination itself could lead to add-
itional risks. To date, clinical trials of dengue vaccine
candidates did not show any ADE related to vaccination.
However, it is necessary to ensure that infection en-
hancement will not occur in vaccinated population some
time due to waning immunity [9]. Increased disease
severity appears to associate with high viral load,
suggesting that antibodies have an influence on the
infectious properties of the virus. The viral load in
secondary infection patients without severe disease is
similar to that in primary infection patients [10].
However, it has been reported that pre-existing an-
tibody in infants did not correlate with increased
viremia and disease severity [11]. In addition, it has
also been demonstrated asymptomatic healthy blood
donors with high dengue viremia did not have de-
tectable antibody [12]. To date, understanding of the
molecular mechanism of ADE has been severely ham-
pered by the lack of an ideal animal model and is
still a mystery. Consequently, there have been few re-
ports to provide in vivo evidence of ADE of DENV
infection [13,14]. In spite of that, it has been proved
that AG129 mouse model could cause many similar-
ities with specific features of human DENV infection
and thus may be an appropriate animal model for the
investigation of ADE in vivo [15].
DENV is an enveloped, positive-stranded RNA virus
and it encodes three structural proteins (capsid, C; enve-
lope, E; pre-membrane, prM) and seven nonstructural
(NS) proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b and
NS5) [16]. The initial assembly of DENV particles occurs
in the endoplasmic reticulum by formation of immature
virions, which contain heterodimers of the E and prM.
The prM protein is a 166-amino-acid protein, which is
believed to acts as a chaperone for correct folding and
assembly of the E protein [17,18]. Subsequently, the viral
envelope proteins are believed to undergo conforma-
tional changes triggered by the low pH in trans-Golgi
network (TGN). Then the endoprotease furin cleaves
prM into M that remains associated with the virus par-
ticle and an N-terminal 91-amino-acid peptide (“pr”)
that dissociates upon release of the virus from the
infected cell, resulting in the formation of mature virions
[19,20]. The cleavage of prM to M is required for DENV
maturation and infectivity.Many studies have shown that prM-specific antibodies
could mediate DENV-specific immune response in
humans [21-25]. These prM-specific mAbs are highly
cross-reactive among four DENV serotypes and, even at
high concentrations, do not neutralize infection but po-
tently promote ADE infection over a broad range of
concentration [24,26]. It has also been suggested that
anti-prM antibodies could render essentially non-in-
fectious imDENV highly infectious [24,27,28]. Recent
studies in infants have also implicated that anti-prM
antibodies could lead to severe disease upon primary in-
fection [29]. These studies on human and mouse anti-
prM mAbs [30-32] suggest that this class of antibodies
have a significant role to enhance DENV infection in
humans. However, most of the epitopes recognized by
these prM-specific antibodies remain unclear.
Viral protein epitopes are pivotal in the pathogenesis
of virus infection and in the development of effective
vaccines [33,34]. Therefore, the identification of B-cell
epitopes for DENV prM antibodies can provide im-
portant information for the understanding of the pa-
thogenesis of DENV infection and contribute to the
development of dengue vaccine. In the case of DENV,
many efforts have been made into mapping the epitopes
of E protein [35-39], but only a few epitopes have been
identified on prM protein [40,41]. Consequently, the
precise antigenic structures of prM and their functions
in the immune response and infection pathogenesis re-
main poorly studied.
In the present study, the epitope recognized by prM
mAb 4D10 was identified using a phage-displayed pep-
tide library and comprehensive bioinformatic analysis.
We investigated the neutralizing versus enhancing cap-
acity of the mAb 4D10 and antisera of epitope peptide
PL10 towards standard DENV1-4 particles and imDENV
particles. We found that 4D10 and antibody against epi-
tope peptide PL10 showed broad cross-reactivity and
poor neutralizing acvitity with the four standard DENV
serotypes but significantly enhanced the infectious prop-
erties. In addition, these antibodies remained susceptible
to partially neutralizing imDENV and indeed rendered
virtually non-infectious imDENV highly infectious in
Fc receptor-bearing cells. Taken together, we identified
a novel infection-enhancing epitope on prM protein.
These results may provide some important implications
for a better understanding of the pathogenesis of DENV
infection and advance the development of dengue vaccine.
Methods
Cells
C6/36 cells derived from Aedes albopictus were main-
tained in Modified Essential Medium (GIBCO) supple-
mented with 10% fetal bovine serum (FBS) at 28°C, 5%
CO2. Baby Hamster Kidney-21 (BHK-21) cells derived
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adenocarcinoma LoVo cells derived from left supracla-
vicular region metastasis were cultured in Dulbecco’s
Modified Eagle’s Medium (GIBCO) supplemented with
10% FBS at 37°C, 5% CO2. Human erythroleukemic
K562 cells derived from bone marrow were maintained
in Iscove’s Modified Dulbecco’s Medium (GIBCO) sup-
plemented with 10% FBS at 37°C, 5% CO2. The media
were supplemented with 2 mM L-glutamine, 10mM
HEPES, penicillin (100 U/ml) and streptomycin (100 U/ml).
All cells were purchased from ATCC.
Viruses
DENV1 strain Hawaii (GenBank: EU848545), DENV2
strain New Guinea C (NGC) (GenBank: AF038403),
DENV3 strain H87 (GenBank: M93130), DENV4 strain
H241 (GenBank: AY947539) and JEV (GenBank:
AF315119) were propagated on C6/36 cells. Briefly,
monolayer of C6/36 cells was infected with DENV at
multiplicity of infection (MOI) of 1. The virus superna-
tants were harvested at 72 hours post-infection (hpi),
cleared from cellular debris by low-speed centrifugation,
purified by PEG 8000 precipitation. Fully imDEVN2
NGC strain was produced on furin-deficient LoVo cells
as described before [42]. Briefly, LoVo cells were in-
fected at MOI 10 for 1.5h at 37°C. Then, virus inoculum
was removed and fresh medium was added after washing
the cells twice with PBS. At 72 hpi, the virus particles
were harvested,cleared from cellular debris by low-speed
centrifugation. Subsequently, virus particles were precip-
itated by 40% PEG 8000. The titers of virus were deter-
mined by plaque assay on BHK-21 cells and viral RNA
copy numbers were calculated by real-time quantitative
RT-PCR (qRT-PCR). To assess the growth and infectious
properties of standard DENV2 and imDENV2 at dif-
ferent time point, standard DENV2 and imDENV2 were
cultured in C6/36 cells and LoVo cells respectively at
MOI 10 and virus particles were collected at 24 h time
intervals (24 hpi, 48 hpi, 72 hpi, 96 hpi).
Antibodies
2H2 (IgG2a anti-DENV1-4 prM) and 4G2 (IgG2a anti-
all flavivirus E) hybridomas were purchased from ATCC.
4D10 (IgG1 anti-DENV1-4 prM) hybridoma was gener-
ated according to standard procedures [43]. Briefly, Six-
week-old female BALB/c mice were subcutaneously
immunized twice at 2-week intervals with purified prM
in Freund’s complete or incomplete adjuvant (Sigma).
Three days after a final immunization, spleen cells from
the mice and mouse myeloma SP2/0 cells were fused
and maintained according to the standard procedure
[43]. The hybridoma producing 4D10 (IgG1) was screened
by enzyme-linked immunosorbent assay (ELISA), western
blot analysis and indirect immunofluorescence assay(IFA). 4D10 (IgG1) was purified from mouse ascites using
protein A affinity columns (GE).
Human serum samples
Human serum samples were obtained from DENV2 pa-
tients or healthy adults after consent and approvals from
the ethical committee of Haizhu district center for dis-
ease control and prevention of Guangzhou, China. The
study was also approved by the Animal Experimentation
Ethics Committee of Sun Yat-sen University. Acute
DENV2 infection was identified by virus isolation during
C6/36 cell culture and DENV serotype-specific reverse
transcriptase-PCR (RT-PCR) [44]. DENV infection was
also confirmed by DENV-specific IgG and IgM capture
ELISA [45].
Phage-displayed biopanning procedures
The Ph.D.-12™ Phage Display Peptide Library Kit was
purchased from New BioLabs Inc. Four successive
rounds of biopanning were carried out according to the
manufacturer’s instruction manual. Briefly, 100 μl mAb
4D10(100 μg/ml) was coated overnight at 4°C on 96-well
plate and blocked at 4°C for 2h. The plates were then
washed five times with washing buffer, and phages
[1.5×1011 plaque-forming units (PFU)] were incubated
at 37°C for 1h with coated antibody. The wells were
washed five times with TBST. Then, the bound phages
were eluted with 100 μl of 0.2 M glycine-HCl (pH 2.2)
plus 1 mg of BSA/ml and were then neutralized with
15 μl of 1 M Tris–HCl (pH 9.1). The eluted phages were
amplified and titrated in Escherichia coli ER2537 culture.
The amplified phages were used in the next cycle. After
four rounds of biopanning, 62 phage clones were se-
lected and screened by ELISA and further characterized
by DNA sequencing.
ELISA
To identify immunopositive phage clones, the ELISA
plates were coated overnight at 4°C with 100 μl mAb
4D10(100 μg/ml) and blocked 2h at 4°C. Phage clones
were added to the wells (1.5 × 1011 pfu in 100 μl per
well) and incubated with agitation for 2h at room
temperature. The plates were then washed with wa-
shing buffer, and 1:5000-diluted horseradish-peroxidase
(HRP)-conjugated anti-M13 antibody (Pharmacia) in
blocking buffer was added. The plates were incubated at
room temperature for 1 h with agitation and washed
with washing buffer. HRP/substrate solution was added
to each well and incubated at room temperature. The re-
action was stopped with 2 N H2SO4 and the plates were
read using a microplate reader set at 450 nm.
For antibody-binding assay, ELISA plates were coated
with 100 μl per well of individual synthetic peptides at a
concentration of 10 μg/ml. For the sensitivity binding
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ging from 20 to 0.31 μg/ml) were coated to the plates.
Anti-prM mAb diluted in 1:200 was added to each
well. Subsequently, the wells were incubated with cor-
responding HRP-conjugated anti-mouse IgG, then the
same steps as above were followed and absorbance
was measured.
DNA sequencing and computer analysis
The DNA sequences of ELISA-positive phage clones
were sequenced with the 96 gIII sequencing primer:
5’-TGAGCGGATAACAATTTCAC-3’, based on phage
cloning vector (GenBank: L08821), as described by the
manufacturer’s instructions (New England BioLabs Inc.).
Sequences of DNA inserted into target phage clones
were translated into amino acid sequences and aligned
with that of prM protein of DENV2 using Standard pro-
tein–protein BLAST [blast] and ClustalW Multiple Se-
quence Alignment [clustal] public software.
Bioinformatics analysis of DENV2 prM B-cell epitopes
Using DNASTAR software and ExPaSy multiple bio-
information software, we performed general evaluation
of DENV prM B-cell epitopes including Hopp &Wood
hydrophilicity; Granthan polarity; Jameson & Wolf anti-
genicity; Bhaskaran & Ponnuswamy flexibility; Emini ac-
cessibility; Deleage & Roux alpha-helix regions; Deleage
& Roux beta-turn regions [46-51]. Considering the re-
sults of phage biopanning together, one predominant
epitope peptide PL10 (13IVSRQEKGKS22) (GenBank:
AAC59275), control peptides PH10 (3LTTRGGEP HM12)
(GenBank: AAC59275) and PM10 (SQNPPHRHQS)
(Ph.D.-12™ Phage Display Peptide Library Kit, New
BioLabs Inc.) were synthesized (purity >95%, China
Peptides Co., Ltd).
Competitive-inhibition assay
In competitive-inhibition experiments, coating with anti-
prM mAb, blocking, and washing were performed.
Synthetic peptide PL10 was added 0.1 μg per well and
corresponding phage clones were added simultaneously.
Then the same steps as described in “ELISA” were fol-
lowed. The inhibition percentage was calculated as follows:
inhibition (%) = [(OD450 without competitor −OD450
with competitor)/ OD450 without competitor] ×100%.
Immunization assay and protection assay in adult
Balb/c mice
All procedures involving animals were approved by the
Animal Experimentation Ethics Committee of Sun Yat-sen
University and carried out by a licensed individual with an
ethical approval number of 2012/0081.
Animals were purchased from the Center of Expe-
rimental Animal of the Sun Yat-Sen University. Fourgroups (PL10 coupled to KLH, PH10 coupled to KLH,
PM10 coupled to KLH, and PBS), each comprising of
ten adult female Balb/c mice (4–6weeks old), were in-
traperitoneally injected with 100 μg of immunogen
emulsified in complete Freund’s adjuvant for the first
immunization. Mice were then injected at week 2 and 4
with the peptides and Freund’s incomplete adjuvant. The
mice were bled on week 0, 2, 4 and 6 via tail vein
according to NC3Rs standard procedures, and the anti-
peptide antibody titer of mice sera was determined by
ELISA.
Two weeks after the last immunization, mice were
infected with DENV2 NGC strain (106 PFU/mouse)
through peritoneal injection. Blood samples were col-
lected at day 0.25, 1, 2, 3, 4 and 5 via tail vein according
to NC3Rs standard procedures. Then, all animals were
euthanized by using Carbon dioxide (CO2) according to
NC3Rs standard procedures and the experiment was ter-
minated. Viral RNA was extracted from 140 μl serum al-
iquots using QIAamp Viral RNA mini kit (Qiagen). The
viral RNA copy numbers were quantified by qRT-PCR.
Western blot analysis
DENV infected C6/36 cells were treated with 1% triton
X-100, the lysates were run on 12% SDS polyacryra-
mide gels and transferred onto polyvinylidene difluoride
(PVDF) membranes (Amersham). The membranes were
then blocked with PBS containing 5% skimmed milk and
probed with prM-specific antibodies for 2 h at room
temperature. Subsequently, membranes were detected
with HRP-conjugated anti-mouse IgG and developed with
enhanced chemiluminescence reagents (ECL, Thermo
Fisher Scientific).
Indirect immunofluorescence assay (IFA)
C6/36 cells were infected with DENV1-4 and JEV. Cells
were then fixed with acetone at −20°C for 20 min and
washed three times with PBS. Cells were incubated with
a 100-fold dilution of prM-specific antibodies. After
60 min of incubation at 37°C, cells were washed three
times with PBS. Cells were then reacted with a 200-fold
dilution of Alexa-Fluor-488-conjugated anti–mouse IgG
(Invitrogen) for 45 min at 37°C, washed five times with
PBS. After washing, cells were treated with DAPI and
detected using a fluorescent microscope.
Real-time quantitative RT-PCR (qRT-PCR)
Viral RNA copy numbers were quantified by qRT-PCR
as described previously [52]. Briefly, Viral RNA was
extracted from 140 μl serum aliquots using QIAamp
Viral RNA mini kit (Qiagen). DENV1-4 serotypes uni-
versal primers (Forward Primer: 5'-GCATATTGACG
CTGGGAGAGA-3', Reverse Primer: 5'-GCGTTCTGT
GCCTGGAATG-3') and Probe (5'-FAM-AGATCCTGC
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of DENV1 strain Hawaii (GenBank: EU848545), were se-
lected by using Primer Express software. cDNA was syn-
thesized from viral RNA ( 37°C for 15 min, 85°C for 5 s)
by using PrimeScript® RT reagent Kit (Takara). DNA was
amplified for 40 cycles (95°C for 10 s, 95°C for 5 s, 60°C
for 20 s) by using Premix Ex Taq™ (Takara). The concen-
tration of viral RNA copy numbers was determined
using a standard curve based on a cDNA plasmid cont-
aining the gene fragment of 349 bp in 3' noncoding
region of DENV1 strain Hawaii.
Plaque forming assay
The titres of virus were determined by a plaque forming
assay on BHK-21 cells and expressed as PFU per ml.
Briefly, virus was serially 10-fold diluted and incubated
with BHK-21 cell monopayers for 2h at 37°C. The
monolayers were then overlaid with 1.2% (w/v) carboxy-
methylcellulose and incubated at 37°C for 7 days. The
wells were stained with 1% (w/v) crystal violet dissolved
in 4% (v/v) formaldehyde to visualize the plaques.
Plaques were counted and the virus titer was expressed
as PFU/ml.
Plaque reduction neutralization test (PRNT)
Neutralizing activity of prM-specific antibodies was de-
termined by the plaque reduction neutralization test
(PRNT). Briefly, 2-fold serially diluted antibody was
mixed with approximately 50 PFU DENV and incubated
for 1h at 37°C. The mixtures were then transferred to
BHK-21 cell monolayers followed by the plaque forming
assay described above. The percentage of plaque reduc-
tion was calculated as previously described [53].
Antibody-dependent infection enhancement assay
Serial 2-fold dilutions of antibody were incubated with
an equal volume of DENV for 1h at 37°C then trans-
ferred to K562 cells at MOI of 1and incubated at 37°C
for 4 days. Supernatants were then harvested and viral
RNA levels were assessed by qRT-PCR as described
above. Alternatively, after 3 days, infected K562 cells
were determined by flow cytometry.
Flow cytometry
The infected K562 cells were fixed and permeabilised
with Cytofix/ Cytoperm™ Fixation/Permeabilization kit
(BD) at 4°C for 20 min. DENV antigens were then stained
with 4G2 conjugated to Alexa-Fluor-488 (Invitrogen) at
4°C for 30 min. The cells were washed twice, and percent
infection was determined by flow cytometry.
Statistical analysis
Statistical analyses were performed in GraphPad Prism
5.0 software. ANOVA Tukey’s post-hoc statistical testswere used for pairwise comparisons of multiple groups.
A p value of less than 0.05 was considered significant.
Results
Characterization of DENV-specific mAb 4D10
ELISA assays showed that 4D10, like 2H2 (positive con-
trol antibody), detected DENV1-4 infected cells but not
JEV (negative control antigen for the specificity of the
antibody 4D10) infected cells (Figure 1A). Western blot
analysis confirmed that the specificity of 4D10 and 2H2
for DENV1-4 prM protein (Figure 1B). To further prove
the DENV serotypes specificity of 4D10, we also per-
formed an indirect immunofluorescence assay (Figure 1C).
Only DENV infected C6/36 cells were detected by 4D10
and 2H2, JEV infected cells were not reactive. These re-
sults suggested that 4D10 is similar to 2H2, which has
been proved to be a DENV cross-reacting prM mAb [40].
We concluded that 4D10 is a DENV serocomplex cross-
reactive prM mAb that does not cross-react with other
flaviviruses.
To confirm further the specificity reactivity of 4D10,
an antibody competitive- inhibition assay was carried
out to determine whether the 4D10 competed with
DENV2 patient sera for reactivity with DENV2. The re-
action activity of DENV2 patient sera with DENV2 was
inhibited markedly by 4D10 with the inhibition percen-
tage from 33% to 61% (Figure 1D).
Screening of phage-displayed peptide library with
anti-DENV prM mAb 4D10
To select the immunopositive phage clones, anti-
DENV1-4 prM mAb (4D10) was purified from the as-
cites using the protein A affinity column. The bound
phage clones were selected after four biopanning rounds.
Fifty-five of 62 selected phage clones had significant en-
hancement of reactivity to mAb 4D10 but not to normal
mouse serum (NMS) (Figure 2). Inserted nucleotides
of the selected positive phage clones were sequenced
and translated to peptide sequences (Table 1). Through
alignment of phage-displayed peptide sequences using
DNASTAR software, the binding motif of antibody 4D10
was shown to be VS/GKTE (Table 1). We next compared
the binding motif with the primary amino acid sequence
of the prM protein of DENV1-4, YFV, WNV, JEV and
TBEV and found that the epitope for antibody 4D10
corresponded only to amino acid residues 14 to18 of
DENV1-4 prM protein but not to other flaviviruses
(Table 2). Notably, the epitope for antibody 4D10 is only
conserved among four DENV serotypes.
General evaluation of DENV prM epitopes with
bioinformation software
In order to select the predominant epitopes of DENV
prM, we performed general evaluation of DENV prM
Figure 1 Characterization of prM mAb 4D10. (A, B and C) Cross-reactivity of 4D10 with four DENV serotypes and JEV (negative control
antigen for the specificity of the antibody 4D10) determined by ELISA (A), western blot (B) and IFA (C). These results showed that only DENV1-4
infected C6/36 cells could be detected with 4D10 and 2H2 (positive control antibody) but not JEV infected cells. Normal mouse serum (NMS) had
no such reactivity with all flaviviruses. (D) Competitive inhibition of DENV2 patient sera binding to DENV2 by mAb 4D10. Competitive ELISA was
performed using 4D10 as competitor of DENV2 patient sera. The percentage of inhibition is also shown. Data are expressed as means of at least
three independent experiments. The error bars represent standard deviations (SD). If there is no error bar, it is not that no variations among three
independent experiments but that the variations are too small to show in the figure. * P < 0.05 vs 4D10.
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Figure 2 Selection for specific phage clones bound to mAb 4D10. (A) Twenty-seven phage clones reacted strongly with 4D10. (B) Twenty-
eight phage clones reacted strongly with 4D10.After the fourth round of biopanning, 55 phage clones from 62 selected phage clones showed
significant reactivity to mAb 4D10 but not to normal mouse serum (NMS). Data are expressed as means of at least three independent
experiments. The error bars represent standard deviations (SD). If there is no error bar, it is not that no variations among three independent
experiments but that the variations are too small to show in the figure.
Table 2 Alignment of amino acid residues 14 to 18 of the
prM proteins of flaviviruses with binding motif VS/GKTE
Virusa Amino acid sequence
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licity; Granthan polarity; Jameson & Wolf antigenicity;
Bhaskaran & Ponnuswamy flexibility; Emini accessibility;
Deleage & Roux alpha-helix regions and beta-turn re-
gions. The epitopes are most likely fall on the regions
that have shown in Table 3. According to the empirical
rules that the positions of B-cell epitopes ought to be lo-
cated at the region which contained more beta-turns but
fewer alpha-helixes, as well as be hydrophilic, polar, anti-
genic, flexible, and accessible, we found that one of pos-
sible B-cell epitopes was located in amino acid residuals
12–26 (Table 3).
Properties analysis of synthetic peptide
To verify that peptide sequence corresponding to amino
acid residuals 14–18 of the prM protein of DENV was
indeed recognized by the antibody 4D10, synthetic
peptide PL10 (13IVSRQEKGKS22) binding assays wereTable 1 Amino acid sequence analysis of selected phages
screened against prM mAb 4D10









Notes: Phage-displayed consensus amino acids are shown in bold.carried out. As shown in Figure 3A, 4D10 specifically
reacted with the synthetic peptide PL10, whereas control
antibody 4G2 (anti-flavivirus E mAb) did not reacted
with PL10. For the sensitivity binding assay, the syn-
thetic peptide PL10 bound the antibody in a concentra-
tion-dependent manner. Two control peptides PH10
(3LTTRGGEPHM12) and PM10 (SQNPPHRHQS) were
not reactive (Figure 3B).
We next evaluated whether the synthetic peptide PL10
could be react with anti-DENV1-4 mice sera. Synthetic
peptide PL10 was recognized by anti-DENV1-4 mice
sera, whereas it was not recognized by anti-JEV mice









Notes: aThe protein sequences of DENV1, DENV2, DENV3, DENV4, WNV, JEV,
YFV and TBEV were retrieved from GenBank with accession numbers
EU848545, AF038403, M93130, AY947539, DQ211652, AF315119, X03700 and
AY182009 respectively. The amino acids identical between the binding motif
and prM protein are shown in bold.
Table 3 Prediction of B-cell epitopes of DENV prM protein
Predicted criteria B epitope regions
Hopp & Wood hydrophilicity 5–10, 12–26, 42–47, 56–66, 83–94,
102–112, 115–122
Granthan polarity 5–9, 15–20, 58–63, 83–91, 116–118
Jameson & Wolf antigenicity 3–12, 14–24, 26–33, 40–53, 56–73,
81–94, 111–118, 130–133
Bhaskara & Ponnuswamy flexibility 5–9, 15–20, 55–66, 85–91, 103–106,
108–118
Emini accessibility 3–9, 15–21, 24–29, 47–50, 56–62,
82–92, 104–110, 119–124
Deleage & Roux alpha-helix regions 5–12, 16–19, 23–34, 44–58, 62–83,
94–104, 127–135, 142–150
Deleage & Roux beta-turn regions 5–9, 16–26, 28–32, 55–63, 84–89,
114–118
Notes: The possible predominant B epitope region showing conformity with
the result of phage-displayed peptide library is shown in bold.
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serocomplex cross-reactive epitope-based peptide.
To confirm further the phage-displayed peptide was
the epitope of antibody 4D10, a peptide competitive-
inhibition assay was performed to determine whether
the PL10 peptide competed with corresponding phage
clones for reactivity with 4D10. The reaction activity of
antibody 4D10 with the corresponding phage clones was
inhibited markedly by PL10 at 0.1 μg per well with the
inhibition percentage from 34% to 69% (Figure 3D). The
results showed that the synthetic peptide and corre-
sponding phage clones competed for the same antibody-
binding site. Together, these findings suggest that 4D10
recognizes a new epitope on the N-terminal segment of
DENV1-4 prM protein.
Then, we evaluated the reactivity of synthetic peptide
PL10 with DENV2 patient serum samples. PL10 was
able to detect 19 serum samples obtained from 20
DENV2 patients (Figure 3E). The sensitivity of PL10
serologic test was 95%. In addition, the level of antibody
varied among patients. In contrast, all of the serum sam-
ples collected from 20 healthy adults were shown to be
seronegative (Figure 3F).
Immunogenicity of synthetic peptide on Balb/c mice
The antibody titer values were measured after immu-
nization of Balb/c mice with PL10 coupled to KLH,
PH10 coupled to KLH, PM10 coupled to KLH or PBS.
Sera of preimmunization group were tested at 1:100 di-
lution to yield the values of background. The antibody
titer of sera from mice immunized with PL10 was re-
markably higher than that of the sera from mice immu-
nized with PH10, PM10 and PBS (P <0.05). And there
was a significant increase of antibody titer of PL10 after
the second boost immunization (Figure 4).Protection response in adult Balb/c mice
Two weeks after the last immunization, groups of
mice were infected with DENV2 NGC strain (106 PFU/
mouse). The viral RNA copy numbers of sera were
quantified by qRT-PCR (Figure 5). We detected high
levels of viral RNA in all groups at day 0.25 and 1 post-
infection, but the viral RNA copies were significantly re-
duced in all the groups at day 2, 3, 4 and 5 post-
infection. In spite of that, the vial RNA levers in the
PL10 group were remarkably higher than that in groups
of PH10, PM10 and PBS at day 0.25 and 1 post-infection
(P <0.05).Infectious properties of standard DENV2 and imDENV2
The growth and specific infectivity of the viruses were
measured by qRT-PCR and plaque forming assay re-
spectively. As shown in Figure 6A, we determined the
viral RNA copies by qRT-PCR and found that LoVo and
C6/36 cells released comparable viral RNA copies at
each time point examined. This indicates that the cap-
acity of releasing viral particles is not impaired in furin-
deficient LoVo cells. In both cell lines, we detected
maximal virus particles released at 72 hpi. Next, we de-
termined the infectious properties of the distinct virus
preparations by plaque forming assay. The infectious
titer of imDENV2 was severely reduced than that of
virus produced in the C6/36 cells at any given time point
(Figure 6B and C). Subsequently, we calculated the ratio
of viral RNA copies (copies/ml) to infectious titer (PFU)
for each of the virus samples (Figure 6D). The virus-
equivalent particles per PFU of LoVo cells was remark-
ably higher than that of C6/36 cells. These results
showed that the specific infectivity of imDENV was at
least 10, 000-fold lower compared with that of virus pro-
duced in C6/36 cells.Plaque reduction neutralization test
Neutralizing activities of mAb 4D10 and anti-PL10 sera
for standard DENV1-4 and imDENV2 were assessed
using a standard plaque reduction neutralization assay.
We found that 4D10 and anti-PL10 sera were unable to
completely neutralize infection (Figure 7). Instead, neu-
tralization level ranged from 33.3% to 59.2%, and the
partial neutralization was cross-reactive among the four
virus serotypes. These antibodies did not exhibit a high
level of neutralization. Although infectivity of imDENV2
was severely reduced, it remained partially susceptible to
neutralization and the titration curve for DENV2 pro-
duced in LoVo and C6/36 cells were similar (Figure 7).
These results indicate that mAb 4D10 and anti-PL10
sera could not potently neutralize standard DENV1-4
and imDENV2.
Figure 3 Properties analysis of synthetic peptide PL10. (A) Specific reactivity of PL10 with antibody 4D10 (anti-DENV1-4 prM mAb). The
synthetic peptide PL10 could react with mAb 4D10 but control antibody 4G2 (anti-flavivirus E mAb) could not. (B) The sensitivity binding assay of
synthetic peptides PL10 and two control peptides (PH10 and PM10) with mAb 4D10. The synthetic peptide PL10 bound the antibody in a
concentration-dependent manner, but two control peptides had no reactivity with 4D10. (C) ELISA reactivities of synthetic peptide PL10 with
immunized mice sera. Synthetic peptide PL10 was recognized by anti-DENV1-4 mice sera, whereas it was not recognized by anti-JEV mice sera
and normal mice sera (NMS). (D) Competitive inhibition of phage clone binding to mAb 4D10 by synthetic peptide PL10. Competitive ELISA was
performed using PL10 as competitor of its corresponding phage clones. The percentage of inhibition is also shown. (E and F) ELISA reactivities of
synthetic peptide PL10 with serum samples from 20 DENV2-infected patients (E) and 20 healthy adults (F). PH10 and PM10 were used as control.
Data are expressed as means of at least three independent experiments. The error bars represent standard deviations (SD). If there is no error bar,
it is not that no variations among three independent experiments but that the variations are too small to show in the figure. * P < 0.05 vs PL10
at 0.1 μg.
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Figure 4 Time course of antibody titer levels induced in mice
immunized with PL10, PH10, PM10 and PBS. Four groups (PL10
coupled to KLH, PH10 coupled to KLH, PM10 coupled to KLH, and
PBS), each comprising of ten adult female Balb/c mice (4–6weeks
old), were immunized thrice with 2-week intervals using 100 μg of
the PL10, PH10, PM10 or an equal volume PBS. PH10 ,PM10 and PBS
were used as control. The mice were bled on week2, 4 and 6 via
tail vein, and the anti-peptide antibody titer of mice sera was
determined by ELISA. The antibody titer of PL10 was remarkably
higher than that of the antisera from mice immunized with PH10,
PM10 and PBS at each time point. Data are expressed as means of
at least three independent experiments. The error bars represent
standard deviations (SD); * P < 0.05 vs control groups (PH10, PM10
and PBS).
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anti-PL10 sera
We carried out ADE assays with Fc receptor-bearing
K562 cells to determine the enhancing capacity of
4D10, anti-PL10 sera and 4G2 (positive control) towardsFigure 5 Quantification of viral RNA levels in immunized mice
after inoculated with DENV2 NGC strain. Two weeks after the last
immunization, mice were infected with DENV2 NGC strain through
peritoneal injection. Viral RNA levels of sera were quantified by
qRT-PCR at day 0.25, 1, 2, 3, 4 and 5 post-infection. PH10 and PM10
were used as control. The vial RNA levers in the PL10 group were
always higher than that in groups of PH10, PM10 and PBS at any
given time point. Data are expressed as means of at least three
independent experiments. The error bars represent standard
deviations (SD); * P < 0.05 vs control groups (PH10, PM10, PBS).standard DENV1-4 and imDENV2 using flow cytometry
and qRT-PCR. Previous studies have shown that 4G2
was capable of enhancing infection of standard DENV1-4
and imDENV2 [24,54]. Consistent with these reports, en-
hancement of infection was observed for 4G2 in this study
(Figure 8C and F). According to flow cytometry results, en-
hancement of infection was observed for 4D10 and anti-
PL10 sera with a peak of nearly 80% increase (Figure 8A
and B), the enhanced infection percentage varied from
2.2% to 79.3% over a large range of antibody concentration
among four DENV serotypes. Next we tested enhance-
ment of imDENV2 using a constant amount of virus-
equivalent particles compared to DENV2. The results
showed that the normally non-infectious imDENV2 could
be rendered much more infectious in the presence of
4D10 and anti-PL10 sera than DENV2 did (Figure 8A
and B). These results were further exemplified by asses-
sing viral RNA copies in infected supernatants using qRT-
PCR (Figure 8D and E). Consistent with flow cytometry
results, 4D10 and anti-PL10 sera led to a significant in-
crease of viral load over a broad antibody concentration
range (P <0.05). Taken together, both 4D10 and anti-PL10
sera could potently enhance infection of standard DENV
and imDENV2.
Discussion
It has been previously reported that anti-prM mAbs pro-
vided cross-protection against all four DENV serotypes
[40,55]. However, the potential importance of these
prM-containing particles and prM antibodies in DENV
infection pathogenesis has been ignored for a long time
as numerous functional studies have reported that fully
immature particles are noninfectious [56]. Interestingly,
recent studies on human and mouse anti-prM mAbs
[24-32] suggest that prM-specific mAbs have a signifi-
cant role to enhance infection of standard DENV and
imDENV particles. However, there have been few at-
tempts to locate the epitopes of prM ptotein. To gain a
deeper understanding of the antigenic structures of prM
and their functions in human immune response to
DENV, we identified the epitope of prM mAb 4D10 and
investigated the ability of mAb 4D10 and antibody
against epitope peptide PL10 to mediate ADE infection
of standard DENV1-4 and imDENV particles.
In this study, we generated and characterized a DENV
serocomplex cross-reactive prM mAb 4D10. Then, we
successfully mapped the epitope of 4D10 to amino acid
residues 14 to 18 of DENV1-4 prM protein using phage
display technology. The epitope peptide showed con-
formity with one region (amino acid residues 12 to 26)
predicted by bioinformatics analysis. Consequently, the
epitope peptide (13IVSRQEKGKS22) was synthesized for
further study. We confirmed that PL10 was a DENV se-
rocomplex cross-reactive epitope peptide and showed to
Figure 6 The infectious properties of standard DENV2 and imDENV2 determined by qRT-PCR and plaque forming assay. The viral RNA
copies determined by qRT-PCR (A) and the plaque morphology and infectious titer determined by plaque forming assay (B and C) of DENV2
produced in C6/36 and LoVo cells at each time point. (D) The ratio of viral RNA copies (copies/ml) to infectious titer (PFU) for the distinct virus
preparations. The specific infectivity of imDENV2 was significant lower than that of DENV2 generated in C6/36 cells. Data are expressed as means
of at least three independent experiments. The error bars represent standard deviations (SD). If there is no error bar, it is not that no variations
among three independent experiments but that the variations are too small to show in the figure. * P < 0.05 vs C6/36.
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successfully distinguish DENV serotypes from other
flaviviruses in immunized mice sera. The high degree of
antibody cross-reactivity among different flaviviruses
has been a diagnostic challenge to distinguish various
flaviviral infections, and this limitation is apparent forFigure 7 Partial neutralizing activities of mAb 4D10 and anti-PL10 ser
50 PFU DENV and incubated for 1 h at 37°C. Neutralizing activities were ev
(A) and anti-PL10 sera (B) exhibited partial neutralizing activities against sta
three independent experiments. The error bars represent standard deviatio
independent experiments but that the variations are too small to show inmembers of DENV serotypes [57,58]. It has been prev-
iously reported that prM-specific antibodies could be
applied as a diagnostic marker to distinguish previous
infection of DENV from JEV [22]. Thus, it is remarkable
that the DENV-specific epitope in prM has great po-
tential to improve DENV serological diagnostic tests.a. Serial 2-fold dilutions of antibody were mixed with approximately
aluated by plaque reduction assay using BHK21 cells. Both 4D10
ndard DENV-4 and imDENV2. Data are expressed as means of at least
ns (SD). If there is no error bar, it is not that no variations among three
the figure.
Figure 8 Infection enhancement of DENV mediated by 4D10, anti-PL10 sera and 4G2 in K562 cells. Serial 2-fold dilutions of antibody were
incubated with an equal volume of DENV for 1 h at 37°C then transferred to K562 cells at MOI of 1. Infected K562 cells were determined by flow
cytometry at 3 days post infection (A, B and C). Viral RNA copies of infected supernatants were measured by qRT-PCR at 4 days post infection
(D, E and F). Both 4D10 and anti-PL10 sera could potently enhance infection of standard DENV1-4 and imDENV. NMS and IgG (mouse IgG1 and
mouse IgG2a) isotype control antibodies were used as controls. Data are expressed as means of at least three independent experiments. The
error bars represent standard deviations (SD). If there is no error bar, it is not that no variations among three independent experiments but that
the variations are too small to show in the figure. * P < 0.05vs No Ab.
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infected patient sera but not with sera of healthy donors,
suggesting that the epitope peptide PL10 could possibly
be used as a serologic reagent in the diagnosis of DENV-
infected patients.
The control peptide PH10 (3LTTRGGEPHM12) may
be the possible epitope region of prM protein predicted
by bioinformatics analysis, but the antibody titer of
PH10 was not high enough. For synthetic peptides to
serve as effective immunogens, they must comprise po-
tential antigenic sites to promote B cell interaction [59].
Immature particles produced in furin-deficient LoVo
cells have very high levels (94%) of prM-containing par-
ticles. Interestingly, both mammalian cells (BHK-21 or
Vero) and insect cells (C6/36) infected with DENV re-
lease as many as 30% prM- containing immature parti-
cles [42,60] suggesting that cleavage of prM to M is not
very effective. Therefore, cells infected with DENV re-
lease a heterogeneous mixture of not only fully mature
(containing M) and immature (containing prM) but also
partially mature virus particles (containing prM and M)
[42,61,62]. Previous studies have demonstrated that ma-
ture particles and partially mature particles were infec-
tious whereas immature particles were virtually non-
infectious [24,27,42,56]. The maturation state of virus
particles can influence the neutralizing and enhancing
capacity of antibodies direct against DENV surface pro-
teins [24,27,63]. We detected the specific infectivity of
the LoVo-released virus particles and found that the in-
fectious properties of imDENV2 was 10,000-fold lower
compared to that of C6/36-cultured standard virus prep-
arations. This agrees with previous results [27,42] and
proves that immature virus is virtually non-infectious.
Antibodies induced by DENV infection may have dual
roles: obstruct infection through neutralization activity
or enhance viral infection via ADE activity. Consistent
with prior studies [24-27,31,41,42], the mAb 4D10 and
antibody against epitope peptide PL10 described in the
present study showed broad cross-reactivity and poor
neutralizing activity with the four standard DENV se-
rotypes and imDENV but significantly enhanced the in-
fectious properties. These results suggested 4D10 and
anti-PL10 sera were infection-enhancing antibodies and
PL10 was infection-enhancing epitope. We found mAb
4D10 and antibody against PL10 showed different neu-
tralizing against different virus strains, suggesting the ex-
istence of structural differences in the epitope region.
The mechanism of virus neutralization and ADE in the
presence of antibody against prM is still elusive. Consis-
tent with these results, during protection assay in vivo,
our data clearly suggested the epitope peptide PL10 in-
deed elicit enhancing antibodies and promote DENV
replication. The partial neutralization of antibodies
against prM to standard dengue viruses implies thatsome infectious particles within the virus preparation
are partially mature (containing a mixture of prM and
M) and also indicates that prM antibodies have the
capacity to block the infectivity of partially mature
particles. Meanwhile, partial cleavage of prM from the
viral surface reduces available antigens for neutraliza-
tion activity. The cross-reactive among four DENV se-
rotypes, together with partial cleavage of prM, makes
dengue viruses susceptible to ADE by antibody against
prM [24,56]. It was recently shown that anti-prM anti-
bodies could render essentially non-infectious imDENV
particles highly infectious. The prM antibodies bind to
the virion surface prM antigens and facilitate efficient
binding and cell entry of virus-antibody complexes into
Fc receptor-bearing cells following which the endosomal
furin clears prM into M and renders immature particles
infectious [24,27]. Taken together, our results support
the notion that antibodies against prM can enhance
infectivity of prM-containing immature and partially
mature DENV particles due to an interaction with Fc re-
ceptor expressed on immune cells.
As shown in Figure 8A and B, at low dilution of anti-
body, enhancing and neutralizing activities are mixed
and enhancement is suboptimal, so little or no infection
enhancement is found. Then, enhanced viral growth oc-
curs at a higher dilution. At some dilution of antibody,
optimal viral infections occur and peak enhancement is
observed. At a still higher dilution, the concentration of
infectious antibody–virus complexes is not great enough
to elicit the system response and the infection enhance-
ment is gradually lost [64]. The peak infection enhance-
ment also need a large number of virus receptors on
FcR-bearing cells, the efficient cell entry of virus, the via-
bility of virus in the cytosol, and capability to accomplish
all steps to achieve assembly and final release of virus
particles.
Since recent studies found that DENV particles re-
leased from infected cells contained as many as 30%
prM particles, the infectious potential of immature parti-
cles may have significant implications for understanding
of the dengue pathogenesis. In the early stages of a pri-
mary infection, immature particles fail to enter host cells
in the absence of antibodies, and therefore are of minor
importance in disease development. On the other hand,
prM-specific antibody response will activate the infectiv-
ity of fully immature particle upon secondary infection,
and increase the number of infectious particles.
The epitope recognized by our own anti-prM antibody
was located in amino acid residuals 14–18 of the prM
protein and was different from the published sequence
recognized by other anti-prM mAb 2H2 (mapped to
amino acid residuals 40–49) and 70-21 (mapped to ami-
no acid residuals 53–67) [40,41]. Previous studies have
shown that 2H2 provided cross-protection against all
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demonstrated that 2H2 could enhance the infectivity of
standard DENVV and imDENV [27,65,66]. Also, anti-
body 70–21 as well as many other prM mAbs has been
reported to enhance DENV infectivity [24,26,27,31]. Our
results support that anti-prM antibodies could en-
hance infectious properties of DENV and prM epi-
topes could be not protective but infection enhancing.
We propose that the length of epitope sequence has
an important role to mediate ADE infection. For long
epitope peptide sequences, they may contain two or
more epitopes, which may be immunodominant or
cryptic. These findings suggest that antigenic struc-
tures of prM and their functions are complicated and
not well studied.
Most current dengue vaccines contain native dengue
prM, it may be important to consider better vaccine
approaches that eliminate ADE activities induced by
infection-enhancing epitopes on prM during vaccine de-
sign [24]. Vaccine candidates that eliminate pathogenic
infection-enhancing epitopes may thus become increas-
ingly important. Most importantly, identification of the
epitopes on prM protein will provide new insights for
further understanding of humoral immune responses to
DENV at the epitope level. However, to our knowledge,
there have been few reports of epitopes mapping to
aim at prM protein. Here, we report a novel infection-
enhancing epitope on dengue prM, the findings from
our study may have significant implications for future
vaccine design and facilitate understanding the patho-
genesis of DENV infection.
Conclusions
We mapped the epitope of 4D10 to amino acid residues
14 to 18 of DENV1-4 prM using a phage-displayed pep-
tide library and comprehensive bioinformatic analysis.
Then, we found that this epitope was infection-enhancing.
These findings may provide important information for the
understanding of the pathogenesis of DENV infection at
epitope level and contribute to the development of dengue
vaccine.
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